Trials / Completed
CompletedNCT01678807
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 195 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of two doses (6 Development Units \[DU\] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis. The primary hypothesis is that at least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-8237 6 DU | |
| BIOLOGICAL | MK-8237 12 DU | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2012-09-05
- Last updated
- 2017-09-15
- Results posted
- 2017-02-13
Source: ClinicalTrials.gov record NCT01678807. Inclusion in this directory is not an endorsement.